Johnson & Johnson (NYSE:JNJ) shares sold by Dana Investment Advisors Inc.

VaselineOctober 2, 2024

0 4 minutes read

Dana Investment Advisors Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,751 shares of the company’s stock after selling 319 shares during the period. Holdings of Dana Investment Advisors Inc. in Johnson & Johnson were worth $6,979,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Inçalta Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $27,000. MFA Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $44,000. Fairfield Financial Advisors LTD purchased a new position in Johnson & Johnson in the second quarter valued at about $46,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after buying an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s shares.

Johnson & Johnson price performance

JNJ opened at $162.02 on Wednesday. The company has a 50 day moving average of $162.50 and a two hundred day moving average of $154.21. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a market cap of $389.93 billion, a P/E ratio of 10.10, a P/E/G ratio of 2.69 and a beta of 0.53.

Want more great investment ideas?

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue was up 4.3% compared to the same quarter last year. In the same quarter in the previous year, the business posted EPS of $2.80. On average, analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. This represents a dividend of $4.96 on an annualized basis and a yield of 3.06%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider trading at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. Insiders own 0.16% of the company’s shares.

Analysts set new price targets

Several research firms have commented on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, 19 July. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.21.

View Johnson & Johnson’s latest stock report

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.